Case report: Secretory carcinoma of the breast with ETV6-NTRK3 fusion: clinicopathological features and molecular confirmation by FISH in two cases - Top-Institutions - MDSpire

Case report: Secretory carcinoma of the breast with ETV6-NTRK3 fusion: clinicopathological features and molecular confirmation by FISH in two cases

  • By

  • Xiaoyu Sun

  • Jiaqi Liu

  • July 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Department of Pathology, Zibo
    Department of Pathology, Zibo

    Zibo, Shandong

    Key Differentiators

    • Pathology

  • #2

    medical facility
    medical facility

    Unknown, Unknown

    Key Differentiators

    • General Medicine

  • #3

    Bumrungrad International Hospital
    Bumrungrad International Hospital

    Bangkok, Thailand

    Key Differentiators

    • Oncology

  • #4

    Arkansas Children’s Hospital
    Arkansas Children’s Hospital

    Little Rock, Arkansas

    Key Differentiators

    • Pediatric Oncology

  • #5

    University of Arkansas for Medical Sciences
    University of Arkansas for Medical Sciences

    Little Rock, Arkansas

    Key Differentiators

    • Medical Research

Original Source(s)

Case report: Secretory carcinoma of the breast with ETV6-NTRK3 fusion: clinicopathological features and molecular confirmation by FISH in two cases

  • by Xiaoyu Sun, Jiaqi Liu

  • July 2, 2026

Related Content

Smartphones Spot Ocular Malignancies

Could a smartphone-based AI system bring ocular oncology screening directly into the patient’s home?

  • July 2, 2026

  • 3 min
ASCO26: Sara Tolaney, MD, MPH, ASCENT-04

Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free survival compared to standard therapy.

  • July 1, 2026

  • 1 min
ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

  • July 1, 2026

  • 1 min